CompletedNot Applicable

Effect of High-intensity Intermittent Sprinting on Appetite Control on Obese Volunteers

Norway12 participantsStarted 2010-05

Plain-language summary

Several studies have shown that high intensity intermittent sprints (HIIS) are more effective than moderate intensity continuous cycling (MICC) in reducing fat mass and improving insulin resistance in normal weight individuals. Changes in the appetite-regulatory system in response to exercise are likely to explain, at least partially, the better outcome observed after HIIS. Unfortunately, there are no studies comparing the impact of different types of acute aerobic exercise on the release of appetite-regulating hormones, subjective feelings of appetite and subsequent energy intake (EI). The primary objective of this study is to investigate the effects of acute isocaloric bouts of HIIT and MICC or a short duration sprint, in comparison with a resting control condition, on the postprandial release of appetite-regulating hormones, subjective feelings of appetite and subsequent EI in obese individuals. The investigators hypothesize that an isocaloric session of HIIS will result in a better short-term appetite control compared with MICC, by reducing hunger feelings and subsequent food intake more than MICC and by inducing a larger increase in the release of satiety gut peptides compared with the MICC.

Who can participate

Age range

18 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * an inactive lifestyle, * weight stable on the previous 3 months, * not currently dieting to loose weight * restraint score derived from the Three Factor Eating Behaviour Questionnaire ≤12 Exclusion Criteria: * history of coronary heart disease, * type 1 or type 2 diabetes, * anaemia, * gout, * depression or other psychological disorders, * eating disorders, * drug or alcohol abuse within the last two years, * current medication known to affect appetite or induce weight loss and hypertension.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Changes in gut peptides

Timeframe: Blood samples taken in fasting and postprandially for 3h

Trial details

NCT IDNCT01143363

SponsorNorwegian University of Science and Technology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Obesity trials